Role of the Liver and Kidney in the Desulphation of Heparin in vivo

Summary

Heparin radiolabelled with ¹²⁵I was given intravenously to intact, bilaterally nephrectomised or completely hepatectomised rats in the presence and absence of 1 mg unlabelled heparin/kg. Plasma samples were collected and analysed by gel filtration chromatography and affinity chromatography on Polybrene-Sepharose, which binds sulphated glycosaminoglycans. Radiolabel in the plasma was associated with both intact heparin and fully desulphated macromolecular carbohydrate chains. Levels of intact heparin in plasma from control rats decreased with time at both doses with a concomitant increase in desulphated material. Livers accumulated the greatest amounts of radiolabel on a per organ basis. Hepatectomy both increased levels of radiolabel in plasma and decreased amounts of desulphated heparin produced, indicating that the liver was the major site of desulphation. Even after removal of the liver, the desulphated metabolite comprised approximately 15% of radiolabelled material at all times and doses, suggesting an additional site of GAG desulphation which may be the vascular endothelium. The kidneys contributed significantly to in vivo desulphation of heparin only at the high dose.

• References

• 1 Comper WD, Tay M, Wells X, Dawes J. Desulphation of dextran sulphate during kidney ultrafiltration. Biochem J 1994; 297: 31-34
• 2 Dawes J, Pepper DS. Catabolism of low dose heparin in man. Thromb Res 1979; 14: 845-860
• 3 MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Metabolism of sodium pentosan polysulphate in man catabolism of iodinated derivatives. Thromb Haemost 1984; 51: 321-325
• 4 Dawes J, Pepper DS. Human vascular endothelial cells catabolise exogenous glycosaminoglycans by a novel route. Thromb Haemost 1992; 67: 468-472
• 5 Hop wood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment Mol Biol Med 1990; 7: 381-404
• 6 Muir H. Structure and enzymic degradation of mucopolysaccharides. In: Lysosomes and Storage Diseases. Hers HG, Van Hoof F. (eds) London: Academic Press; 1973. pp 79-104
• 7 Yanagishita M, Hascall VC. Metabolism of proteoglycans in rat ovarian granulosa cell culture. Multiple intracellular degradative pathways and the effect of chloroquine J Biol Chem 1984; 259: 10270-10283
• 8 Campbell JH, Rennick RE, Kalevitch SG, Campbell GR. Heparan sulfatedegrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res 1992; 200: 156-167
• 9 de Sousa JF, Nader HB, Dietrich CP. Sequential degradation of chondroitin sulfate in molluscs. J Biol Chem 1990; 265: 20150-20155
• 10 Teien AN. Heparin elimination in patients with liver cirrhosis. Thromb Haemost 1977; 38: 701-706
• 11 Hiebert L. The uptake of heparin by liver sinusoidal cells in normal and atherosclerotic rabbits. Thromb Res 1981; 21: 383-390
• 12 Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-935
• 13 Losito R, Gattiker H, Bilodeau G. Heparin excretion in intact and hepatectomized rats. Thromb Haemost 1981; 45: 146-149
• 14 Shanberge JN, Gruhl M, Kitani T, Ambegaonkar S, Kambayashi J, Nakagawa M, Lenter D. Fractionated tritium-labelled heparin studied in vitro and in vivo. Thromb Res 1978; 13: 767-783
• 15 Ruggeri A, Guizzardi S, Franchi M, Morocutti M, Mastacchi R. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II. Organ distribution in rats Arzheim-Forsch 1985; 35: 1517-1519
• 16 Stehle G, Friedrich EA, Sinn H, Wunder A, Harenberg J, Dempfle CE, Maier-Borst W, Heene DL. Hepatic uptake of a modified low molecular weight heparin in rats. J Clin Invest 1992; 90: 2110-2116
• 17 Caranobe C, Barret A, Gabaig AM, Dupony D, Sie P, Boneu B. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and a low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res 1985; 40: 129-133
• 18 Boneu B, Dol F, Caranobe C, Sie P, Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-291
• 19 Dawes J, Hodson BA, Pepper DS. The adsorption, clearance and metabolic fate of dermatan sulphate administered to man-studies using a radioiodinated derivative. Thromb Haemost 1989; 62: 945-949
• 20 Wayneforth BH. Experimental and surgical techniques in the rat. London: Academic Press; 1980
• 21 Patel KR, Li MP, Baldeschwieler JD. Suppression of liver uptake of liposomes by dextran sulphate 500. Proc Natl Acad Sci USA 1983; 80: 6518-6822
• 22 Dawes J, Prowse CV, Pepper DS. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma, serum and urine. Thromb Haemost 1985; 54: 630-634
• 23 Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-577
• 24 Dawes J. Measurement of the affinities of heparins, naturally occuring glycosaminoglycans, and other sulphated polymers for antithrombin III and thrombin. Anal Biochem 1988; 174: 177-186
• 25 Shively JE, Conrad HE. Formation of anhydrosugars in the chemical depolymerisation of heparin. Biochem 1976; 15: 3932-3942
• 26 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985; 845: 196-203
• 27 Vannucchi S, Pasquali F, Porciatti F, Chiarugi V, Magnelli L, Bianchini P. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells. Thromb Res 1988; 49: 373-383
• 28 Fleck C, Bomer A, Kretzschmar M, Machnik G, Sprott H, Zimmerman T, Keil E, Braunlich H. Liver function after bilateral nephrectomy. Liver 1992; 12: 319-325